Simplex in Medical Technology

CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

... In prior tests involving L.E.A.P.S. herpes simplex vaccines, CEL-SCI and other researchers showed ... a good indicator for protection against herpes simplex as well. Dr. Borthakur, of the University of ... from a disease-related protein, such as a herpes simplex virus (HSV) glycoprotein to make a vaccine that ...

Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections

... in the dermis and epidermis, where it surrounds and fuses with herpes simplex virus and disrupts the outer envelope of the pathogen," Flack said. ... so it is not absorbed into the bloodstream." Because the herpes simplex virus causes both cold sores and genital herpes, there is a strong ...

AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine

... a mixture of in-house and partnered programs. The AlphaVax technology is currently being used to advance vaccines for cytomegalovirus, herpes simplex virus, respiratory syncytial virus, a range of cancers, influenza, HIV and a number of biodefense targets. The AlphaVax headquarters and R&D ...

AlphaVax Announces Promising Results in Melanoma Studies

... clinical trial is planned for later this year. In addition to cancer immunotherapy programs, AlphaVax is developing vaccine products for herpes simplex virus, influenza, respiratory syncytial virus, HIV and a number of biodefense targets. The AlphaVax headquarters and R&D facilities are located ...

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

... the sexual transmission of HIV and other sexually transmitted diseases. Laboratory studies have shown that PRO 2000 is active against HIV, herpes simplex virus, chlamydia and the bacterium that causes gonorrhea. Vaginally applied PRO 2000 has been found to afford protection in mouse models for genital ...

Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented

... develop and market ganciclovir ophthalmic gel, available in Europe for the treatment of ocular viral infections for more than 10 years. Herpes simplex keratitis is the leading cause of corneal blindness in the US, with 20,000 new primary cases of diagnosed each year and an additional 28,000 cases of ...

ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests

... In other preclinical studies, ANX-201 has shown broad-spectrum antiviral activity against HIV-1, HIV-2, human and avian influenza viruses, and herpes simplex viruses 1 and 2 (HSV-1 and HSV-2). About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical company focused ...

CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein

... studies, CEL-1000 has also previously been shown to protect animals against infection against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria. CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a ...

Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection

... potential to advance medical treatment of herpes simplex keratitis in the U.S. Herpes simplex keratitis is a leading cause of corneal blindness ... in the journal Archives of Ophthalmology, herpes simplex keratitis affects approximately 50,000 people ...

MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial

... The virus, called NV1020, is a type of herpes simplex virus modified so that it selectively replicates ... intrahepatic infusion of oncolytic herpes simplex virus nv1020 prior to second-line chemotherapy ... shown that single doses of the oncolytic herpes simplex virus NV1020 administered regionally are ...

CEL-SCI's Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals

... CEL-1000 has previously been shown to be protective in animal challenge studies against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria. CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a ...

ANX-201 Drug Combination Demonstrates Synergistic Activity Against Human and Bird Flu Viruses

... In preclinical studies, ANX-201 has shown broad-spectrum antiviral activity against HIV-1, HIV-2, human and avian influenza viruses, and herpes simplex viruses 1 and 2 (HSV-1 and HSV-2). ADVENTRX plans to initiate a Phase 1/2 clinical trial of ANX-201 as a component of multi-drug therapy for the ...

CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals

... studies, CEL-1000 has also previously been shown to protect animals against infection against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria. CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce ...